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Abstract
We recently reported that the nonselective cyclooxygenase (COX) inhibitor
ketorolac attenuated sweating but not cutaneous vasodilation during moder-
ate-intensity exercise in the heat. However, the specific contributions of COX-
1 and COX-2 to the sweating response remained to be determined. We tested
the hypothesis that COX-1 but not COX-2 contributes to sweating with no
role for either COX isoform in cutaneous vasodilation during moderate-inten-
sity exercise in the heat. In thirteen young males (22  2 years), sweat rate
and cutaneous vascular conductance were measured at three forearm skin sites
that were continuously treated with (1) lactated Ringer’s solution (Control),
(2) 150 lmmolL1 celecoxib, a selective COX-2 inhibitor, or (3)
10 mmol L1 ketorolac, a nonselective COX inhibitor. Participants first rested
in a non heat stress condition (≥85 min, 25°C) followed by a further 70-min
rest period in the heat (35°C). They then performed 50 min of moderate-
intensity cycling (~55% peak oxygen uptake) followed by a 30-min recovery
period. At the end of exercise, sweat rate was lower at the 150 lmolL1 cele-
coxib (1.51  0.25 mgmin1cm2) and 10 mmolL1 ketorolac
(1.30  0.30 mgmin1cm2) treated skin sites relative to the Control site
(1.89  0.27 mgmin1cm2) (both P ≤ 0.05). Additionally, sweat rate at the
ketorolac site was attenuated relative to the celecoxib site (P ≤ 0.05). Neither
celecoxib nor ketorolac influenced cutaneous vascular conductance throughout
the experiment (both P > 0.05). We showed that both COX-1 and COX-2
contribute to sweating but not cutaneous vasodilation during moderate-inten-
sity exercise in the heat in young men.
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Introduction
Nonsteroidal antiinflammatory drugs (NSAIDs) are
widely utilized by the general population for management
of pain, fever, and inflammation. NSAIDs function pri-
marily through inhibition of the cyclooxygenase (COX)
enzyme. While the prevalence of NSAID use is relatively
high in older adults, they are also commonly used by
young individuals to manage pain and/or inflammation,
especially in those engaged in competitive athletics (War-
ner et al. 2002; Da Silva et al. 2011). Exercise results in
hyperthermia, which is exacerbated under high ambient
temperature conditions. Previous work has evaluated how
oral intake of NSAIDs modulates body temperatures and/
or the heat loss responses of sweating and cutaneous
vasodilation (Charkoudian and Johnson 1999; Bradford
et al. 2007; Bruning et al. 2013). However, NSAID inges-
tion acts systemically, inducing both local and central
effects. To better understand the mechanisms by which
NSAIDs modulate sweating and cutaneous vasodilation
during exercise in the heat, it is important to isolate the
influence of local COX inhibition on these heat loss
responses, independent of any systemic effects.
The local mechanisms underpinning the heat loss
responses have been extensively studied and several key
modulators have been identified including nitric oxide
synthase (Kellogg et al. 1995; McNamara et al. 2014;
Meade et al. 2015; Fujii et al. 2016), K+ channels (Brunt
et al. 2013; Louie et al. 2016, 2017), neurotransmitters
released from sympathetic cholinergic nerves (Kellogg
et al. 1998, 2012), and COX (McCord et al. 2006; Fujii
et al. 2014b). Regarding the latter, we recently reported
that nonselective COX inhibition (via ketorolac) attenu-
ated sweat rate in young habitually active adults during
moderate-intensity exercise in the heat (Fujii et al.
2014b). However, the specific role of each COX isoform
(COX-1 and COX-2) remains unclear. Human eccrine
sweat glands possess COX-1 with no clear expression of
COX-2 (Muller-Decker et al. 1999), suggesting that COX-
1 alone may contribute to the sweating response.
However, this possibility has not yet been evaluated. Elu-
cidating which COX isoform contributes to the sweating
response during exercise in the heat is important, since
although most NSAIDs block both COX isoforms, some
block either one (e.g., a low dose of aspirin more selec-
tively inhibits COX-1) (Ornelas et al. 2017).
In contrast to the sweating response, we recently
demonstrated that dual blockade of COX-1 and COX-2
had no effect on cutaneous vasodilation during moderate-
intensity exercise in the heat (Fujii et al. 2014b). While
this finding may be interpreted as a lack of a role for
either COX isoform in modulating cutaneous vasodilation
under these conditions, it is also possible that COX-1 and
COX-2 confer opposing vasoactive effects (i.e., vasocon-
striction vs. vasodilation), thus warranting further scru-
tiny. Indeed, it is believed that COX-1 predominantly
produces the vasoconstrictor thromboxane A2, whereas
COX-2 creates the vasodilator prostacyclin (Bates and
Lau 2005; Rovati et al. 2010; Feletou et al. 2011). Assess-
ing the effects of selective COX inhibitors on vascular
responses during heat stress would act to clarify the role
of this enzyme in the cutaneous vasodilatory response to
exercise-induced heat stress.
The purpose of this study was to evaluate the hypothe-
sis that in young men, COX-1 but not COX-2 contributes
to the sweating response during moderate-intensity exer-
cise in the heat. We also hypothesized that neither COX-1
nor COX-2 would influence cutaneous vasodilation.
Materials and Methods
Ethical approval
The current study was approved by the University of
Ottawa Health Sciences and Science Research Ethics
Board and complied with the guidelines set forth by the
Declaration of Helsinki. All participants gave verbal and
written informed consent prior to participation.
Participants
Thirteen young habitually active males volunteered to
participate in the study. We tested males only to avoid
any potential sex-related differences in the regulation of
cutaneous vasodilation and sweating (Gagnon et al. 2013;
Greaney et al. 2014; Fujii et al. 2015a). All participants
were screened for cardiovascular, respiratory, metabolic,
and skin diseases before participating. Participants were
nonsmoking, and not taking any prescription medica-
tions. Mean (SD) age, body mass, height, surface area,
and peak oxygen uptake were: 22  2 years,
80.0  8.8 kg, 1.79  0.07 m, 1.99  0.13 m2, and
47.9  5.1 mLkg1min1, respectively.
Experimental design
All participants completed one screening and one experi-
mental session. Prior to each session, participants were
instructed to refrain from engaging in heavy exercise and
consuming over-the-counter medications including
NSAIDs (e.g., aspirin and ibuprofen have half-lives of less
than 6 h (Schiodt et al. 2002)), vitamins, and minerals
for a minimum of 48 h, caffeinated beverages or alcohol
for at least 12 h, and food for 2 h.
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During the screening session, body mass was measured
using a digital weight scale platform (model CBU1500X;
Mettler Toledo, Schwerzenbach, Switzerland) with a
weighing terminal (model IND560; Mettler Toledo Inc.,
Mississauga, ON, Canada), while height was assessed
using an eye-level physician stadiometer (Detecto, model
2391, Webb City, MO). These two measurements were
used to calculate body surface area using the equation de-
veloped by Du Bois and Du Bois (Du Bois and Du Bois
1916). Body fat percentage was estimated through body
density measured via the hydrostatic weighing technique.
Peak oxygen uptake was determined through an incre-
mental cycling exercise protocol performed on a semire-
cumbent cycling ergometer (Corival Recumbent, Lode
B.V., Groningen, the Netherlands). Participants main-
tained a pedaling rate of 60–100 rpm at a starting resis-
tance of 80 W, which was subsequently increased by
20 Wmin1 until volitional fatigue. Ventilatory and
metabolic data were collected using an automated indirect
calorimetry system (Medgraphic Ultima, Medical Graphic
Corporation, St Paul, MN).
The experimental session was performed on a day fol-
lowing and separated from the screening session by a
minimum of 48 h. Upon arrival at the laboratory, partici-
pants voided their bladder, after which pretrial body mass
was measured on a weighing terminal (Mettler Toledo
Inc.). Participants were then seated on a surgical bed in a
non heat stress ambient temperature condition of 25°C.
Three microdialysis fibers (30 kDa cutoff, 10 mm mem-
brane; MD2000, Bioanalytical Systems, West Lafayette,
IN) were inserted into the dermal layer of the skin on the
left dorsal forearm. Under aseptic conditions, a 25-gauge
needle was inserted into the skin (~2.5 cm in length). The
microdialysis fiber was then threaded through the lumen
of the needle, after which the needle was removed leaving
the fiber embedded in the forearm skin. Each fiber was
secured with surgical tape, and separated from adjacent
fibers by 2–4 cm.
After the insertion of the fibers, the participant was
transferred to a thermal chamber (Can-Trol Environmen-
tal Systems, Markham, ON, Canada) regulated to 25°C
and 20% relative humidity where they rested while seated
on a semirecumbent cycle ergometer (Corival Recumbent,
Lode B.V.). At this time, the perfusion of the pharmaco-
logical agents with a micro-infusion pump (Model 400,
CMA Microdialysis, Solna, Sweden) was initiated at each
of the three microdialysis sites at a rate of 4 lLmin1.
The sites were perfused with either (1) lactated Ringer’s
solution (Baxter, Deerfield, IL) (Control), (2)
150 lmolL1 celecoxib (Cayman Chemical, Ann Arbor,
MI), a selective COX-2 inhibitor, or (3) 10 mmolL1
ketorolac (Sigma-Aldrich, St. Louis, MO), a nonselective
COX inhibitor. Given that celecoxib is water-insoluble,
the organic solvent dimethyl sulfoxide (Sigma-Aldrich)
was required to make celecoxib solution. In our pilot
work, we found 5% dimethyl sulfoxide to have no effect
on sweating or cutaneous vascular responses relative to a
Control site (i.e., only lactated Ringer’s solution) during
exercise in the heat. Therefore, any difference between the
control (lactated Ringer’s solution) and 150 lmolL1
celecoxib sites should reflect a COX-2 inhibition effect in
the present study. Previous work has demonstrated that
~150 lmolL1 celecoxib maximally inhibits COX-2 (Tac-
conelli et al. 2002). The concentration of ketorolac was
based on previous microdialysis work (Holowatz et al.
2005, 2009; Kellogg et al. 2005; McCord et al. 2006;
Medow et al. 2007; Yamazaki et al. 2007; Fujii et al. 2013,
2014b; Kutz et al. 2015). Drug perfusion continued for a
minimum of 75 min in order to ensure maximal inhibi-
tion of COX. This time period is sufficient to ensure that
any redness associated with fiber insertion had subsided
(Anderson et al. 1994). Drug perfusion continued
throughout the entire experimental protocol to ensure the
sustained blockade of COX.
Following the ≥75 min habituation period in a non
heat stress ambient temperature condition of 25°C, par-
ticipants were monitored for an additional 10 min to
acquire baseline measurements. Thereafter, room temper-
ature was increased to 35°C within 10 min. Thereafter
the participants remained resting on the semirecumbent
cycle ergometer for at least 70 min. Resting measure-
ments at 35°C were recorded during the final 10 min.
Participants then performed 50-min cycling at a moder-
ate intensity (equivalent to ~55% of their predetermined
peak oxygen uptake), which was followed by a 30-min
recovery period. This exercise intensity was chosen to
induce a significant increase in body core temperature
and therefore increases in sweating and cutaneous perfu-
sion, but it was low enough to ensure that a COX-
dependent sweating would occur (Fujii et al. 2014b).
Thereafter, 50 mmolL1 sodium nitroprusside (Sigma-
Aldrich) was infused for 20–25 min at all sites at a rate
of 6 lLmin1 until maximum values for cutaneous per-
fusion were achieved for a minimum of 2 min. Upon
completion of the experimental session, the participant’s
body mass was measured.
Measurements
A sweat capsule specifically designed for use with an intra-
dermal microdialysis probe that covers an area of 1.1 cm2
(Meade et al. 2016) was placed directly over the center of
each microdialysis membrane. The sweat capsules were
attached to the skin with adhesive rings and topical skin
glue (Collodion HV, Mavidon Medical products, Lake
Worth, FL). Dry compressed air from gas tanks located in
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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the temperature-controlled chamber was supplied to each
capsule at a constant flow rate, while water content of the
effluent air was measured with a capacitance hygrometer
(model HMT333, Vaisala, Helsinki, Finland). Long vinyl
tubes were used for connections between the gas tank and
the sweat capsule (inlet), and between the sweat capsule and
the capacitance hygrometer (outlet). Local forearm sweat
rate was measured continuously (5 sec sampling rate) and
calculated from the water content of the effluent air multi-
plied by the flow rate and normalized for the skin surface
area under the capsule (mgmin1cm2).
Cutaneous blood flow (expressed in perfusion units)
was measured at three local sites on the forearm using
laser-Doppler flowmetry (PeriFlux System 5000, Perimed,
Stockholm, Sweden) at a sampling rate of 32 Hz. Inte-
grated seven-laser array laser-Doppler probes (Model 413,
Perimed) were situated directly above the centre of the
membrane of the microdialysis fibers. Cutaneous vascular
conductance (CVC) was evaluated as laser-Doppler flux,
an index of cutaneous blood flow, divided by mean arte-
rial pressure, and expressed as a %max of values from the
maximal absolute CVC protocol. Blood pressure was
determined every 5 min using a manual mercury column
sphygmomanometer (Baumonometer Standby Model,
WA Baum Co, Copiague, NY). Mean arterial pressure
was calculated as diastolic arterial pressure plus one-third
the difference between systolic and diastolic pressures
(i.e., pulse pressure).
Body core temperature was measured by aural canal
temperature (Braun Thermoscan Pro 6000, Welch Allyn,
Skaneateles Falls, NY), which has been shown to closely
track changes in esophageal temperature, especially in the
heat (Taylor et al. 2014). Skin temperature was measured
continuously at four sites (calf, quadriceps, chest, and
biceps) using thermocouple discs (Concept Engineering,
Old Saybrook, CT) attached to the skin with adhesive
rings and surgical tape. Mean skin temperature was esti-
mated as a weighted mean using the local skin tempera-
tures of the calf (20%), quadriceps (20%), biceps (30%),
and chest (30%) (Hardy and Dubois 1938). Skin temper-
ature data was collected using a data acquisition module
(Model 34970A; Agilent Technologies Canada Inc., Mis-
sissauga, ON, Canada). The data was displayed and
recorded using LabVIEW software (National Instruments,
Austin, TX). Heart rate was measured continuously using
a Polar coded WearLink and transmitter, Polar RS400
interface, and Polar Trainer 5 software (Polar Electro,
Kempele, Finland).
Metabolic energy expenditure was measured via indi-
rect calorimetry using electrochemical gas analyzers
(AMETEK model S-3A/1 and CD3A, Applied Electro-
chemistry, Pittsburgh, PA) to determine O2 and CO2 con-
centrations of expired air. Participants wore a fitted
facemask (Model 7600 V2, Hans-Rudolph, Kansas City,
MO) attached to a 2-way T-shape nonrebreathing valve
(Model 2700, Hans-Rudolph). Oxygen uptake and respi-
ratory exchange ratio were calculated from O2 and CO2
concentrations in expired air, and sampled every 30 sec
to estimate metabolic rate.
The urine sample obtained at the start of the experimen-
tal protocol was analyzed with a total solids refractometer
(Model TS400, Reichter Inc., Depew, NY) to evaluate urine
specific gravity, an index of body fluid status.
Data analysis
Based on sweat rate (Stapleton et al. 2014) and cutaneous
vascular (Fujii et al. 2014a) responses obtained in our
previous work, with 80% power and a significance level
of 0.05, a minimal sample size of n = 8 for sweat rate
and n = 9 for CVC was determined. For all variables, a
5-min average was taken for resting periods [under non
heat stress (25°C) and heat stress (35°C) conditions] and
at 10-min intervals during exercise and the subsequent
recovery. For the measurement of maximal cutaneous
blood flow during the sodium nitroprusside treatment,
responses were averaged over the 2-min plateau interval.
Blood pressure and aural canal temperature were manu-
ally recorded every 5 min, and an average of the two val-
ues measured during a 10-min interval were used for
data analysis. Further, due to technical issues some mea-
surements were not recorded for some participants (num-
bers of participants excluded for data analysis are
indicated in parentheses): sweat rate (n = 1), body core
(n = 1) and mean skin (n = 3) temperatures, and heart
rate (n = 1).
Statistical analyses
Sweat rate and CVC data were analyzed with a two-way
repeated-measures analysis of variance (ANOVA) with the
factors of treatment site (Control, 150 lmolL1 cele-
coxib, 10 mmolL1 ketorolac) and time point (resting at
25°C and 35°C and every 10 min during and following
exercise). Maximum absolute CVC (perfusion uni-
tsmmHg1) was analyzed with a one-way repeated-mea-
sures ANOVA with a factor of treatment site. Secondary
variables (body core and mean skin temperatures, heart
rate, and mean arterial pressure) were analyzed with a
one-way repeated-measures ANOVA with a factor of time
point (resting at 25°C and 35°C as well as end-exercise
and end-recovery). When a significant interaction or
main effect was detected, post hoc multiple comparisons
were carried out using a Holm-Bonferroni correction. In
addition, Student’s t-tests were employed where applica-
ble. The level of significance for all analyses was set at
2018 | Vol. 6 | Iss. 17 | e13844
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P ≤ 0.05. All values are reported with a mean  95%
confidence interval (1.96 9 standard error of the mean).
Statistical analyses were conducted using SPSS 25 (IBM,
Armonk, NY).
Results
Sweat rate
Sweat rate during rest in both non heat stress (25°C) and
heat stress (35°C) conditions did not differ between skin
sites (P > 0.05, Fig. 1). During exercise, sweat rates at all
skin sites were increased relative to preexercise rest in the
heat. Compared to Control, both the administration of
celecoxib and ketorolac attenuated sweat rate during exer-
cise in the heat (P ≤ 0.05, Fig. 1). Further, sweat rate at
the ketorolac treated site was lower than that at the cele-
coxib site (P ≤ 0.05, Fig. 1). During postexercise recovery
in the heat, sweat rate remained reduced relative to Con-
trol by ketorolac only (P ≤ 0.05, Fig. 1).
Cutaneous vascular response
Cutaneous vascular conductance did not differ between
skin sites throughout the experimental protocol (Fig. 2).
Likewise, between-site differences in maximal absolute
CVC were not observed (Table 1).
Body temperatures and cardiovascular
responses
In comparison to the non heat stress resting condition,
body core (36.67  0.12°C) and mean skin
(31.86  0.23°C) temperatures increased by 0.27  0.06
and 2.30  0.23°C, respectively during rest in the heat
(35°C) (both P ≤ 0.05). This was paralleled by increases
in heart rate and mean arterial pressure from 67  5 to
72  6 beatsmin1 and from 86  4 to 88  5 mmHg,
respectively (both P ≤ 0.05). At end-exercise, body core
and mean skin temperatures increased by 0.76  0.20
and 1.24  0.17°C above preexercise resting levels in the
heat with concomitant increases in heart rate
(154  10 beatsmin1) and mean arterial pressure
(102  7 mmHg) (all P ≤ 0.05). During the postexercise
recovery period, body core temperature (37.28  0.15°C)
and heart rate (95  5 beatsmin1) remained elevated
above resting values in the heat (both P ≤ 0.05); however,
mean skin temperature (34.49  0.26°C) had returned to
preexercise resting level in the heat (P > 0.05), and mean
arterial pressure (83  5 mmHg) was reduced (P ≤ 0.05).
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Figure 1. Sweat rate recorded at rest during a non heat stress (25°C) and heat stress (35°C) condition as well as during (dark grey shaded
area) and following (light grey shaded area) exercise in the heat (35C). Three intradermal forearm skin sites were continuously treated with
either: (1) lactated Ringer’s solution (Control), (2) 150 lmolL1 celecoxib (specific COX-2 inhibitor), or (3) 10 mmolL1 ketorolac (COX-1 and
COX-2 inhibitor). * Control versus drug treated site (P ≤ 0.05); † 150 lmolL1 celecoxib versus 10 mmolL1 ketorolac (P ≤ 0.05). All values
are expressed as mean  95% confidence interval (n = 12). Resting values are presented as the average of the final 5-min resting values of the
10-min and 70-min resting period at 25°C and 35°C respectively. All values during exercise and recovery periods were obtained by averaging
over the final 5-min of each time interval.
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Body weight and urine specific gravity
Following the experiment, body weight was reduced by
1.3  0.4% from the pre experiment value (P ≤ 0.05).
Urine specific gravity evaluated before starting the experi-
ment was 1.017  0.005. Consequently, participants were
adequately hydrated (urine specific gravity <1.025; (Kene-
fick and Cheuvront 2012)) prior to the experiment.
Discussion
We evaluated the relative contributions of COX-1 and
COX-2 to the regulation of sweating and cutaneous
vasodilation in young adults during exercise in the heat.
We showed that the lone inhibition of COX-2, as well as
the combined inhibition of COX-1 and COX-2, reduced
sweat rate during moderate-intensity exercise in the heat.
The reduction in sweat rate achieved by the combined
inhibition of both isoforms was greater compared to that
achieved by the selective COX-2 inhibition. In contrast to
our first hypothesis, these results suggest that both COX-
1 and COX-2 contribute to the sweating response in
young habitually active men during moderate-intensity
exercise in the heat. Consistent with our second hypothe-
sis, we observed no role for either COX isoform in the
regulation of cutaneous perfusion.
Sweating
We show that COX-2 contributes to the regulation of
sweating during moderate-intensity exercise in the heat
(Fig. 1). This is in contrast to a previous report that was
unable to confirm the presence of COX-2 in human
eccrine sweat glands in vitro (Muller-Decker et al. 1999).
However, that study did not provide the patient charac-
teristics from which the skin biopsies were obtained
(Muller-Decker et al. 1999). We recently showed that
aging attenuates COX-dependent sweating during exercise
(Fujii et al. 2015b). Thus, the lack of histological evidence
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Figure 2. Cutaneous vascular conductance recorded at rest during a non heat stress (25°C) and heat stress (35°C) condition as well as during (dark
grey shaded area) and following (light grey shaded area) exercise in the heat (35°C). Three intradermal forearm skin sites were continuously treated
with either: (1) lactated Ringer’s solution (Control), (2) 150 lmolL1 celecoxib (specific COX-2 inhibitor), or (3) 10 mmolL1 ketorolac (COX-1 and
COX-2 inhibitor). Cutaneous vascular conductance did not differ between sites (P > 0.05). All values are expressed as mean  95% confidence
interval (n = 13). Resting values are presented as the average of the final 5-min resting values of the 10-min and 70-min resting period at 25°C and
35°C respectively. All values during exercise and recovery periods were obtained by averaging over the final 5-min of each time interval.
Table 1. Absolute maximal cutaneous vascular conductance at
the three skin sites.
(perfusion unitsmmHg1)
Control 1.94  0.40
150 lmolL1 celecoxib 2.19  0.36
10 mmolL1 ketorolac 1.93  0.32
Values are expressed as mean  95% confidence interval
(n = 13). Celecoxib is a specific COX-2 inhibitor. Ketorolac is a
nonselective COX inhibitor. There were no between-site differ-
ences (P = 0.89 for a main effect of treatment site).
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for COX-2 in human eccrine sweat glands (Muller-Decker
et al. 1999) may have been due to the age of the subjects
from which the skin biopsies were obtained. It is also
important to note that the above human eccrine sweat
gland study reported the existence of COX-2 in ker-
atinocytes (Muller-Decker et al. 1999). It may be that pros-
taglandins produced in keratinocytes via COX-2 are able to
migrate to eccrine sweat glands via the interstitial space and
ultimately influence the sweating response during exercise
in the heat. Alternatively, a previous in vitro study reported
that COX-2 (generally known as inducible COX) can be
upregulated by heat stress (Rossi et al. 2012). This may
indicate that an increase in mean skin temperature associ-
ated with endogenous heat production during exercise may
upregulate COX-2 to influence the sweating response under
these conditions. Consistent with this possibility, we
showed that the inhibition of COX-2 only attenuated the
sweating response during the later stages of exercise
(≥30 min) when mean skin temperature had reached sus-
tained elevated levels above baseline resting values.
In agreement with our previous work (Fujii et al.
2014b), we demonstrated that nonselective inhibition of
both COX-1 and COX-2 (via ketorolac) reduced sweat
rate during moderate-intensity (~55% peak oxygen
uptake) exercise in the heat (Fig. 1). To evaluate the sepa-
rate influence of COX-1 on the sweating response, we
compared sweat rates between the combined inhibition of
COX-1 and COX-2 (ketorolac) and COX-2 inhibition
only (celecoxib). During exercise we observed a lower
sweat rate at the nonselective inhibition site compared to
that at the COX-2 inhibited site (Fig. 1). While the over-
all contribution of COX-2 appears to be greater, this find-
ing suggests that COX-1 is also involved in regulating
sweating during moderate-intensity exercise in the heat.
In this context, our findings support previous work,
which identified the presence of COX-1 in human eccrine
sweat glands (Muller-Decker et al. 1999). Based on the
end exercise data in Fig. 1, combined COX-1 and COX-2
explains ~30% of the sweating response during exercise in
the heat, and this relative contribution is similar to that
of nitric oxide synthase and the Na-K-2Cl co-transporter
(Fujii et al. 2014b; Louie et al. 2016). Our previous work
demonstrated that COX and nitric oxide synthase work
in an interactive manner to promote the sweating
response during exercise in the heat (Fujii et al. 2014b).
Whether the Na-K-2Cl co-transporter modulates the
sweating response interactively with COX and nitric oxide
synthase requires future study.
Cutaneous vascular response
In contrast to the sweating response, the present study
demonstrated that neither COX isoform plays a role in
mediating cutaneous vasodilation during exercise in the
heat, as well as during pre and postexercise resting condi-
tions in the heat (Fig. 2). We are not aware of any evi-
dence directly or indirectly explaining this differential
effect of COX inhibition on sweating and cutaneous per-
fusion. Several factors have been shown to influence
COX-dependent mechanisms including prostaglandin
receptors, adenylyl cyclase (an enzyme that forms the
important second messenger cAMP in the COX path-
ways), and phosphodiesterase (an enzyme that degrades
cAMP) (Klein et al. 2007). Consequently, future studies
are therefore necessary to elucidate the separate and com-
bined influences of these modulators in the regulation of
end-organ function of the cutaneous vasculature and
eccrine sweat gland, and therefore skin blood flow and
sweating during rest and exercise in the heat.
Although we detected no role of COX in cutaneous
vasodilation during rest, moderate-intensity exercise, or
postexercise recovery in the heat (35°C) in the present
study (Fig. 2) and in our previous work (Fujii et al.
2014b), McCord et al. (2006) did demonstrate a role of
COX in cutaneous vasodilation during a passive heat
stress induced by whole-body heating with a water-per-
fused suit. The reasons underlying the disparate results
between our collective findings and those by McCord
et al. (2006) remain unclear. However, differences in skin
temperature may in part underlie these different findings.
For example, in the present study, mean skin temperature
remained near levels equal to ambient temperature
(~35°C). In contrast, McCord et al. (2006) employed a
passive heating protocol wherein water temperature of the
tube-lined perfusion suit was markedly increased to heat
the body. Such a maneuver typically causes mean skin
temperature to reach ~39°C (Kellogg et al. 2008, 2009;
Brunt et al. 2013). Since the level of heat stress can influ-
ence regulation of COX-2 (Rossi et al. 2012), the greater
mean skin temperature in the study by McCord et al.
(2006) may have led to a greater COX-2 activation,
thereby resulting in a more robust contribution of this
enzyme to the regulation of cutaneous vasodilation. Fur-
ther studies are required to better understand the influ-
ence of skin temperature on COX-dependent cutaneous
vasodilation.
We showed that dual blockade of COX-1 and COX-2
with ketorolac did not affect cutaneous vasodilation dur-
ing exercise in the heat. This response may indicate that
COX-1 and COX-2 have counteracting vasoactive influ-
ences, causing no effect on cutaneous vascular tone dur-
ing exercise in the heat. In line with this notion, it is
thought that COX-1 chiefly produces the vasoconstrictor
thromboxane A2, while COX-2 creates the vasodilator
prostacyclin (Bates and Lau 2005; Rovati et al. 2010;
Feletou et al. 2011). However, in the current study we
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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excluded this possibility, as inhibition of COX-2 alone
had no effect on cutaneous vasodilation during exercise
in the heat (Fig. 2). Taken together, our findings demon-
strate that neither COX-1 nor COX-2 appear to provide
any vasoactive effects in the skin during exercise in the
heat, thereby confirming that these isoforms are not
actively producing counteracting vasoactive substances
under the study conditions tested. Further work is
required to assess this response at increasing levels of heat
stress (as defined by increasing environmental and/or
exercise-induced heat loads).
Perspective and significance
Sweating and cutaneous vasodilation are crucial for heat
dissipation and the regulation of body core temperature
during exercise, especially in the heat. An impairment in
the body’s capacity to dissipate heat can result in a poten-
tially dangerous increase in body core temperature. In this
context, the use of NSAIDs may compromise heat dissi-
pation during exercise in the heat. NSAIDs are COX inhi-
bitors that are widely used for reducing pain, fever, and
inflammation. Although most of these drugs block both
COX isoforms, some selectively block either COX-1
or COX-2 (e.g., low dose aspirin more selectively inhibits
COX-1). Given the widespread use of NSAIDs by young
individuals engaging in regular exercise (Warner et al.
2002; Da Silva et al. 2011), advancing our understanding
of the role of COX-1 and/or COX-2 inhibition on the
regulation of heat loss responses in this population is
important. Our findings suggest that NSAIDs may attenu-
ate the sweating response to an exercise-induced heat
stress. Consequently, young adults may be at greater risk
of developing a heat-related injury. This risk may be exac-
erbated with the consumption of drugs that block both
isoforms (e.g., ibuprofen), unlike NSAIDs which selec-
tively block either the COX-1 or -2 isoform (e.g., cele-
coxib, low-dose aspirin). Given we locally inhibited these
COX isoforms, our results may be more applicable to
conditions in which topical NSAIDs are used for the
treatment of muscle pains (Manoukian et al. 2017; Yan-
cey and Gill 2017). Further studies are required to deter-
mine if the use of oral and topical NSAIDs cause similar
attenuations in heat loss responses. Additionally, work
must be conducted to determine if these responses remain
intact in older adults. As noted above, NSAIDs are com-
monly prescribed to older adults for the treatment of pain
and inflammation as well as for the management of car-
diovascular disease. In view of the fact that a previous
work demonstrated significant impairments in the capac-
ity of older adults (≥40 years) to dissipate heat (Larose
et al. 2013), studies must be conducted to determine if
the use of NSAIDs may aggravate this response.
Conclusion
We show that in young habitually active men, both COX-
1 and COX-2 contribute to sweating, but not cutaneous
vasodilation, during moderate-intensity exercise in the
heat.
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